サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1671156

急性リンパ性/リンパ芽球性白血病治療薬の世界市場：市場規模・シェア・動向、業界分析 (製品別・用途別・性別・最終用途別・地域別)、将来予測 (2025年～2034年)

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Product, Application, Gender, End Use, and Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 117 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
急性リンパ性/リンパ芽球性白血病治療薬の世界市場：市場規模・シェア・動向、業界分析 (製品別・用途別・性別・最終用途別・地域別)、将来予測 (2025年～2034年)
出版日: 2025年02月01日
発行: Polaris Market Research
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、急性リンパ性/リンパ芽球性白血病治療薬の市場規模は2034年までに69億7,000万米ドルに達する見込みです。このレポートは現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

急性リンパ性/リンパ芽球性白血病（ALL）治療薬市場の成長は、この疾患の有病率の増加、治療選択肢の進歩、早期診断に対する意識の高まりなど、いくつかの要因によってもたらされます。免疫療法、特にキメラ抗原受容体（CAR）T細胞療法の台頭は、再発または難治性のALLに苦しむ患者に新たな希望をもたらし、一方、標的療法はフィラデルフィア染色体陽性ALLなど遺伝的に定義されたサブタイプの治療成績を改善しています。

さらに、遺伝子や分子プロファイリングに基づいて治療動向を調整する精密医療へのシフトが、この市場の重要なトレンドです。急性リンパ性/リンパ芽球性白血病治療薬の市場機会は、有効性を高めるための併用療法に関する継続的な研究とともに、医療へのアクセスが改善するにつれて、十分な治療を受けられない地域でも生まれつつあります。

急性リンパ性/リンパ芽球性白血病治療薬市場：分析概要

製品別では、化学療法分野が急性リンパ性/リンパ芽球性白血病治療薬市場収益の最大シェアを占めています。化学療法はALLの標準治療と考えられています。しかし、標的療法分野は、チロシンキナーゼ阻害剤やCAR T細胞療法などの技術革新に牽引され、最も急成長している分野です。

前駆B細胞性ALLは、その有病率の高さから、用途別では支配的なセグメントです。他方、フィラデルフィア染色体陽性ALLセグメントは、標的療法の使用増加に後押しされ、最も高い成長を遂げています。

性別では、男性の方がALLと診断される頻度が高いため、男性セグメントの市場シェアが高いですが、女性セグメントは早期診断の増加や治療成績の改善により高い成長を示しています。

エンドユーザー別では、病院・診療所が幅広い治療を提供していることから、急性リンパ性/リンパ芽球性白血病治療薬市場シェアを独占しています。しかし、免疫療法や幹細胞移植などの高度な腫瘍学的治療に特化していることから、がん治療センターが最も急速に成長しています。

北米は高度な医療インフラと高い治療導入率により世界市場を独占していますが、アジア太平洋は医療アクセスの拡大と先進治療に対する需要の高まりにより、最も高い成長を遂げています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 分析手法

第4章 急性リンパ性/リンパ芽球性白血病治療薬市場の洞察

  • 市場スナップショット
  • 急性リンパ性/リンパ芽球性白血病治療薬の市場力学
    • 促進要因と機会
      • 急性リンパ性/リンパ芽球性白血病の利点に関する認識の向上
      • 世界料理やフュージョン料理の人気が高まり、急性
    • 抑制要因と課題
      • 製品の限界価格が高い
  • PESTLE分析
  • 急性リンパ性/リンパ芽球性白血病治療薬市場の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の急性リンパ性/リンパ芽球性白血病治療薬市場：用途別

  • 主な分析結果
  • イントロダクション
  • フィラデルフィア染色体
  • 前駆B細胞ALL
  • T細胞性ALL

第6章 世界の急性リンパ性/リンパ芽球性白血病治療薬市場：製品別

  • 主な分析結果
  • イントロダクション
  • 化学療法
  • 標的療法
  • 放射線治療
  • 幹細胞移植

第7章 世界の急性リンパ性/リンパ芽球性白血病治療薬市場：性別

  • 主な分析結果
  • イントロダクション
  • 男性用
  • 女性用

第8章 世界の急性リンパ性/リンパ芽球性白血病治療薬市場：最終用途別

  • 主な分析結果
  • イントロダクション
  • 病院・クリニック
  • がん治療センター
  • 研究・学術機関

第9章 世界の急性リンパ性/リンパ芽球性白血病治療薬市場：地域別

  • 主な分析結果
  • イントロダクション
    • 急性リンパ性/リンパ芽球性白血病治療薬市場の評価：地域別 (2020～2034年)
  • 北米
    • 北米：用途別 (2020～2034年)
    • 北米：製品別 (2020～2034年)
    • 北米：性別 (2020～2034年)
    • 北米：最終用途別 (2020～2034年)
    • 米国
    • カナダ
  • 欧州
    • 欧州：用途別 (2020～2034年)
    • 欧州：製品別 (2020～2034年)
    • 欧州：性別 (2020～2034年)
    • 欧州：最終用途別 (2020～2034年)
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋：用途別 (2020～2034年)
    • アジア太平洋：製品別 (2020～2034年)
    • アジア太平洋：性別 (2020～2034年)
    • アジア太平洋：最終用途別 (2020～2034年)
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ
    • 中東・アフリカ：用途別 (2020～2034年)
    • 中東・アフリカ：製品別 (2020～2034年)
    • 中東・アフリカ：性別 (2020～2034年)
    • 中東・アフリカ：最終用途別 (2020～2034年)
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ
  • ラテンアメリカ
    • ラテンアメリカ：用途別 (2020～2034年)
    • ラテンアメリカ：製品別 (2020～2034年)
    • ラテンアメリカ：性別 (2020～2034年)
    • ラテンアメリカ：最終用途別 (2020～2034年)
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第10章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第11章 企業プロファイル

  • Amgen Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Kite Pharma（a subsidiary of Gilead Sciences）
  • Bristol Myers Squibb
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson（via Janssen Pharmaceuticals）
  • Sanofi
  • AbbVie Inc.
  • Servier
  • Spectrum Pharmaceuticals
  • Bluebird Bio
  • Celgene（now part of Bristol Myers Squibb）
  • Jazz Pharmaceuticals
図表

List of Tables:

  • Table 1 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 2 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 3 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 4 Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 5 North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 6 North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 7 North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 8 North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 9 U.S.: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 10 U.S.: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 11 U.S.: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 12 U.S.: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 13 Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 14 Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 15 Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 16 Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 17 Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 18 Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 19 Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 20 Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 21 UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 22 UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 23 UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 24 UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 25 France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 26 France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 27 France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 28 France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 29 Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 30 Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 31 Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 32 Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 33 Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 34 Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 35 Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 36 Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 37 Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 38 Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 39 Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 40 Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 41 Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 42 Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 43 Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 44 Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 45 Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 46 Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 47 Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 48 Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 49 Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 50 Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 51 Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 52 Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 53 Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 54 Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 55 Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 56 Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 57 China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 58 China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 59 China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 60 China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 61 India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 62 India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 63 India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 64 India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 65 Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 66 Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 67 Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 68 Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 69 Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 70 Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 71 Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 72 Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 73 Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 74 Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 75 Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 76 Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 77 South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 78 South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 79 South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 80 South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 81 Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 82 Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 83 Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 84 Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 85 Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 86 Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 87 Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 88 Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 89 Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 90 Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 91 Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 92 Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 93 Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 94 Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 95 Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 96 Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 97 UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 98 UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 99 UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 100 UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 101 Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 102 Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 103 Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 104 Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 105 South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 106 South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 107 South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 108 South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 109 Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 110 Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 111 Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 112 Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 113 Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 114 Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 115 Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 116 Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 117 Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 118 Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 119 Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 120 Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 121 Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 122 Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 123 Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 124 Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 125 Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 126 Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 127 Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 128 Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • Table 129 Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • Table 130 Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • Table 131 Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • Table 132 Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Application
  • Figure 7. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Product
  • Figure 9. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Gender
  • Figure 11. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2024 & 2034 (USD Billion)
  • Figure 12. Market by End-use
  • Figure 13. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2024 & 2034 (USD Billion)
目次
Product Code: PM1242

The acute lymphocytic/lymphoblastic leukemia therapeutics market size is expected to reach USD 6.97 billion by 2034, according to a new study by Polaris Market Research. The report "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Product (Chemotherapy, Targeted Therapy, Radiation Therapy, and Stem Cell Transplantation), Application, Gender, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market growth is driven by several factors such as the increasing prevalence of the disease, advancements in treatment options, and growing awareness about early diagnosis. The rise of immunotherapies, particularly chimeric antigen receptor (CAR) T-cell therapies, offers new hope for patients suffering from relapsed or refractory ALL, while targeted therapies are improving outcomes for genetically defined subtypes such as Philadelphia chromosome-positive ALL.

Additionally, the shift toward precision medicine, where treatments are tailored based on genetic and molecular profiling, is a key trend in the market. Acute lymphocytic/lymphoblastic leukemia therapeutics market opportunities are also emerging in underserved regions as healthcare access improves, alongside ongoing research into combination therapies to enhance effectiveness.

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Report Highlights

Based on product, the chemotherapy segment holds the largest share of the acute lymphocytic/lymphoblastic leukemia therapeutics market revenue. Chemotherapy is considered a standard treatment for ALL. However, the targeted therapy segment is the fastest-growing segment, driven by innovations such as tyrosine kinase inhibitors and CAR T-cell therapies.

Precursor B-cell ALL is the dominant segment, based on application, due to its high prevalence. On the other side, the Philadelphia chromosome-positive ALL segment is experiencing the highest growth, fueled by the increased use of targeted therapies.

The male segment, based on gender, holds a larger market share, as males are more frequently diagnosed with ALL, while the female segment is showing a higher growth, with increasing early diagnosis and improved treatment outcomes.

In terms of end use, the hospitals and clinics segment dominate the acute lymphocytic/lymphoblastic leukemia therapeutics market share, as it offers a broad range of treatments. However, cancer care centers are the fastest growing due to their specialized focus on advanced oncology therapies such as immunotherapies and stem cell transplants.

North America dominates the global market due to advanced healthcare infrastructure and high treatment adoption rates, while Asia Pacific is the highest growing, driven by expanding healthcare access and rising demand for advanced therapies.

Polaris Market Research has segmented the acute lymphocytic/lymphoblastic leukemia therapeutics market report on the basis of product, application, gender, end use, and region:

By Product Outlook (Revenue - USD Billion, 2020-2034)

  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Stem Cell Transplantation

By Application Outlook (Revenue - USD Billion, 2020-2034)

  • Philadelphia Chromosome
  • Precursor B-cell ALL
  • T-cell ALL

By Gender Outlook (Revenue - USD Billion, 2020-2034)

  • Male
  • Female

By End Use Outlook (Revenue - USD Billion, 2020-2034)

  • Hospitals & Clinics
  • Cancer Care Centers
  • Research & Academic Institutes

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Insights

  • 4.1. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Market Snapshot
  • 4.2. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased awareness of the benefits of Acute Lymphocytic/Lymphoblastic Leukemia
      • 4.2.1.2. Rising popularity of global and fusion cuisines Is propelling the Acute
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The high marginal price of the product
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
  • 5.3. Philadelphia Chromosome
    • 5.3.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Philadelphia Chromosome, by Region, 2020-2034 (USD Billion)
  • 5.4. Precursor B-cell ALL
    • 5.4.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Precursor B-cell ALL, by Region, 2020-2034 (USD Billion)
  • 5.5. T-cell ALL
    • 5.5.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by T-cell ALL, by Region, 2020-2034 (USD Billion)

6. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
  • 6.3. Chemotherapy
    • 6.3.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
  • 6.4. Targeted Therapy
    • 6.4.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
  • 6.5. Radiation Therapy
    • 6.5.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Radiation Therapy, by Region, 2020-2034 (USD Billion)
  • 6.6. Stem Cell Transplantation
    • 6.6.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Stem Cell Transplantation, by Region, 2020-2034 (USD Billion)

7. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
  • 7.3. Male
    • 7.3.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Male, by Region, 2020-2034 (USD Billion)
  • 7.4. Female
    • 7.4.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Female, by Region, 2020-2034 (USD Billion)

8. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • 8.3. Hospitals & Clinics
    • 8.3.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Hospitals & Clinics, by Region, 2020-2034 (USD Billion)
  • 8.4. Cancer Care Centers
    • 8.4.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Cancer Care Centers, by Region, 2020-2034 (USD Billion)
  • 8.5. Research & Academic Institutes
    • 8.5.1. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Research & Academic Institutes, by Region, 2020-2034 (USD Billion)

9. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Geography

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 9.3. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - North America
    • 9.3.1. North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
    • 9.3.2. North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
    • 9.3.3. North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
    • 9.3.4. North America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.3.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - US
      • 9.3.5.1. US: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.3.5.2. US: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.3.5.3. US: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.3.5.4. US: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.3.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Canada
      • 9.3.6.1. Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.3.6.2. Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.3.6.3. Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.3.6.4. Canada: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • 9.4. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Europe
    • 9.4.1. Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
    • 9.4.2. Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
    • 9.4.3. Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
    • 9.4.4. Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - UK
      • 9.4.5.1. UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.4.5.2. UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.4.5.3. UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.4.5.4. UK: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - France
      • 9.4.6.1. France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.4.6.2. France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.4.6.3. France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.4.6.4. France: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.7. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Germany
      • 9.4.7.1. Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.4.7.2. Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.4.7.3. Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.4.7.4. Germany: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.8. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Italy
      • 9.4.8.1. Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.4.8.2. Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.4.8.3. Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.4.8.4. Italy: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.9. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Spain
      • 9.4.9.1. Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.4.9.2. Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.4.9.3. Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.4.9.4. Spain: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.10. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Netherlands
      • 9.4.10.1. Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.4.10.2. Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.4.10.3. Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.4.10.4. Netherlands: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.11. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Russia
      • 9.4.11.1. Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.4.11.2. Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.4.11.3. Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.4.11.4. Russia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.12. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Rest of Europe
      • 9.4.12.1. Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.4.12.2. Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.4.12.3. Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.4.12.4. Rest of Europe: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • 9.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Asia Pacific
    • 9.5.1. Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
    • 9.5.2. Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
    • 9.5.3. Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
    • 9.5.4. Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - China
      • 9.5.5.1. China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.5.5.2. China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.5.5.3. China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.5.5.4. China: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - India
      • 9.5.6.1. India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.5.6.2. India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.5.6.3. India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.5.6.4. India: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.7. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Malaysia
      • 9.5.7.1. Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.5.7.2. Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.5.7.3. Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.5.7.4. Malaysia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.8. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Japan
      • 9.5.8.1. Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.5.8.2. Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.5.8.3. Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.5.8.4. Japan: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.9. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Indonesia
      • 9.5.9.1. Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.5.9.2. Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.5.9.3. Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.5.9.4. Indonesia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.10. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - South Korea
      • 9.5.10.1. South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.5.10.2. South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.5.10.3. South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.5.10.4. South Korea: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.11. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Australia
      • 9.5.11.1. Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.5.11.2. Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.5.11.3. Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.5.11.4. Australia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.12. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Rest of Asia Pacific
      • 9.5.12.1. Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.5.12.2. Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.5.12.3. Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.5.12.4. Rest of Asia Pacific: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • 9.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
    • 9.6.2. Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
    • 9.6.3. Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
    • 9.6.4. Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.6.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.6.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - UAE
      • 9.6.6.1. UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.6.6.2. UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.6.6.3. UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.6.6.4. UAE: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.6.7. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Israel
      • 9.6.7.1. Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.6.7.2. Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.6.7.3. Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.6.7.4. Israel: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.6.8. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - South Africa
      • 9.6.8.1. South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.6.8.2. South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.6.8.3. South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.6.8.4. South Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.6.9. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Rest of Middle East & Africa
      • 9.6.9.1. Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.6.9.2. Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.6.9.3. Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.6.9.4. Rest of Middle East & Africa: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
  • 9.7. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Latin America
    • 9.7.1. Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
    • 9.7.2. Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
    • 9.7.3. Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
    • 9.7.4. Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.7.5. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Mexico
      • 9.7.5.1. Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.7.5.2. Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.7.5.3. Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.7.5.4. Mexico: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.7.6. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Brazil
      • 9.7.6.1. Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.7.6.2. Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.7.6.3. Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.7.6.4. Brazil: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.7.7. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Argentina
      • 9.7.7.1. Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.7.7.2. Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.7.7.3. Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.7.7.4. Argentina: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)
    • 9.7.8. Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Rest of Latin America
      • 9.7.8.1. Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application, 2020-2034 (USD Billion)
      • 9.7.8.2. Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product, 2020-2034 (USD Billion)
      • 9.7.8.3. Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender, 2020-2034 (USD Billion)
      • 9.7.8.4. Rest of Latin America: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use, 2020-2034 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Amgen Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Novartis AG
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Pfizer Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Takeda Pharmaceutical Company Limited
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Kite Pharma (a subsidiary of Gilead Sciences)
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Bristol Myers Squibb
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. F. Hoffmann-La Roche Ltd
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Johnson & Johnson (via Janssen Pharmaceuticals)
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Sanofi
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. AbbVie Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Servier
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Spectrum Pharmaceuticals
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Bluebird Bio
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Celgene (now part of Bristol Myers Squibb)
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Jazz Pharmaceuticals
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development